NWBO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NWBO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Northwest Biotherapeutics's Net Cash per Share for the quarter that ended in Dec. 2023 was $-0.08.
The historical rank and industry rank for Northwest Biotherapeutics's Net Cash per Share or its related term are showing as below:
The historical data trend for Northwest Biotherapeutics's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Northwest Biotherapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Net Cash per Share | Get a 7-Day Free Trial | -0.09 | -0.47 | -0.16 | -0.14 | -0.08 |
Northwest Biotherapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Net Cash per Share | Get a 7-Day Free Trial | -0.14 | -0.08 | -0.08 | -0.08 | -0.08 |
For the Biotechnology subindustry, Northwest Biotherapeutics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Northwest Biotherapeutics's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Northwest Biotherapeutics's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as
Net Cash per Share (A: Dec. 2023 ) | |||||||
= | (Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | - | Minority Interest) | / | Shares Outstanding (EOP) |
= | (2.126 | - | 93.638 | - | 0) | / | 1175.46 |
= | -0.08 |
Northwest Biotherapeutics's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as
Net Cash per Share (Q: Dec. 2023 ) | = | (Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | - | Minority Interest) | / | Shares Outstanding (EOP) |
= | (2.126 | - | 93.638 | - | 0) | / | 1175.46 |
= | -0.08 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Northwest Biotherapeutics (OTCPK:NWBO) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Thank you for viewing the detailed overview of Northwest Biotherapeutics's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Navid Malik | director | 1 CHOLMELEY PARK, HIGHGATE, LONDON X0 N6 5ET |
Marnix L Bosch | officer: Chief Technical Officer | 22322 20TH AVENUE SE, STE 250, BOTHELL WA 98021 |
Alton L Boynton | director, officer: Chief Scientific Officer | 22322 20TH AVENUE SE, STE 150, BOTHELL WA 98021 |
Leslie J. Goldman | officer: See Remarks | C/O NORTHWEST BIOTHERAPEUTICS, INC., 4800 MONTGOMERY LANE, SUITE 800, NEW YORK NY 20814 |
Linda F Powers | director, 10 percent owner, officer: President and CEO | 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814 |
Jerry J Jasinowski | director | C/O HARSCO CORP, P O BOX 8888, CAMP HILL PA 17001-8888 |
Jean M. Davis | officer: See Remarks | 4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814 |
Susan B Bayh | director | WELLPOINT, INC., 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204 |
Black Cofer | director | 4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814 |
Woodford Investment Management Llp | 10 percent owner | 27 OLD GLOUCESTER STREET, LONDON X0 WC1N 3AX |
Cf Woodford Equity Income Fund | 10 percent owner | C/O WOODFORD INVESTMENT MANAGEMENT LTD, 9400 GARSINGTON ROAD, OXFORD X0 OX4 2HN |
Cognate Bioservices, Inc. | 10 percent owner | 7513 CONNELLEY DRIVE, HANOVER MD 21076 |
Robert A Farmer | director | 10205 COLLINS AVE PENTHOUSE 6, MIAMI BEACH FL 33154 |
Toucan General Ii, Llc | 10 percent owner | 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814 |
Hemphill Robert F Jr. | 10 percent owner | 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814 |
From GuruFocus
By PRNewswire PRNewswire • 05-04-2022
By PRNewswire • 10-13-2023
By PRNewswire PRNewswire • 06-26-2022
By PRNewswire PRNewswire • 01-06-2023
By PRNewswire PRNewswire • 07-06-2022
By PRNewswire PRNewswire • 06-29-2022
By PRNewswire PRNewswire • 11-17-2022
By PRNewswire PRNewswire • 06-16-2022
By PRNewswire PRNewswire • 02-17-2022
By PRNewswire PRNewswire • 06-06-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.